2 reports of this reaction
3.4% of all BEVACIZUMAB TNJN reports
#9 most reported adverse reaction
PRODUCT USE IN UNAPPROVED INDICATION is the #9 most commonly reported adverse reaction for BEVACIZUMAB TNJN, manufactured by Bio-Thera Solutions, Ltd.. There are 2 FDA adverse event reports linking BEVACIZUMAB TNJN to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 3.4% of all 59 adverse event reports for this drug.
Patients taking BEVACIZUMAB TNJN who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED INDICATION is moderately reported among BEVACIZUMAB TNJN users, representing a notable but not dominant share of adverse events.
In addition to product use in unapproved indication, the following adverse reactions have been reported for BEVACIZUMAB TNJN:
The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:
PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 2 FDA reports for BEVACIZUMAB TNJN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 3.4% of all adverse event reports for BEVACIZUMAB TNJN, making it a notable side effect.
If you experience product use in unapproved indication while taking BEVACIZUMAB TNJN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.